Discounted Cash Flow (DCF) Analysis Levered
Aridis Pharmaceuticals, Inc. (ARDS)
$2.21
+0.01 (+0.45%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.86 | 2.76 | 8.84 | 28.33 | 90.83 | 291.20 | 933.53 | 2,992.72 | 9,594.12 | 30,756.95 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -17.56 | -24.27 | -8.16 | -20.48 | -0 | -1,797.53 | -5,762.55 | -18,473.67 | -59,223.15 | -189,858.41 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.70 | -0.68 | -0.17 | -0.37 | -0 | -63.47 | -203.48 | -652.31 | -2,091.18 | -6,703.93 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -18.26 | -24.95 | -8.33 | -20.84 | -0 | -1,861 | -5,966.03 | -19,125.98 | -61,314.33 | -196,562.35 |
Weighted Average Cost Of Capital
| Share price | $ 2.21 |
|---|---|
| Beta | 1.133 |
| Diluted Shares Outstanding | 9.17 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.132 |
| Total Debt | - |
| Total Equity | 20.26 |
| Total Capital | - |
| Debt Weighting | - |
| Equity Weighting | - |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.86 | 2.76 | 8.84 | 28.33 | 90.83 | 291.20 | 933.53 | 2,992.72 | 9,594.12 | 30,756.95 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.56 | -24.27 | -8.16 | -20.48 | -0 | -1,797.53 | -5,762.55 | -18,473.67 | -59,223.15 | -189,858.41 |
| Capital Expenditure | -0.70 | -0.68 | -0.17 | -0.37 | -0 | -63.47 | -203.48 | -652.31 | -2,091.18 | -6,703.93 |
| Free Cash Flow | -18.26 | -24.95 | -8.33 | -20.84 | -0 | -1,861 | -5,966.03 | -19,125.98 | -61,314.33 | -196,562.35 |
| WACC | ||||||||||
| PV LFCF | - | - | -0 | - | - | - | - | - | ||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -200,493.59 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -19.99 |
| Equity Value | - |
| Shares Outstanding | 9.17 |
| Equity Value Per Share | - |